Table 1 Baseline patient and treatment characteristics: (n = 48)

Median Age (range)

70 years (47.1 – 85.2)

Median Pre-Treatment PSA (range)

10.0 ng/mL (3.6 – 150.0)

 ≥20 ng/mL

8 (17 %)

Gleason Score

 7

27 (56 %)

  3 + 4

15 (31 %)

  4 + 3

12 (25 %)

 8-10

21 (44 %)

T Stage

 T1c

12 (25 %)

 T2a

13 (27 %)

 T2b

3 (6 %)

 T3a,b

20 (42 %)

# High Risk^a

34 (71 %)

Median Duration HT (range)

6 months (0 – 28)

 None

3 (6 %)

 3 months

12 (25 %)

 4–6 months

15 (31 %)

 7–12 months

8 (17 %)

 24–28 months

7 (15 %)

 Unknown

3 (6 %)

CTV Dose

 19 Gy

23 (48 %)

 21 Gy

25 (52 %)

Median Follow-up (range)

42.7 months (5.3 – 82.9)

# PSA Follow-up Measurements

 Median (range)

8.5 (1 – 24)

 Median Post HT (range)

7 (1 – 19)